Africa CDC plans to present evidence to World Health Organization vaccine advisers in support of testing whether Merck's licensed Ebola vaccine, Ervebo, offers at least partial protection against the Bundibugyo virus driving the outbreak in the Democratic Republic of the Congo, Bloomberg reported at the end of July.
The move matters because it addresses the central gap in the response. There is no licensed vaccine for Bundibugyo ebolavirus, and the outbreak has become the largest ever recorded in the DRC, with WHO reporting 3,605 confirmed cases and 1,587 deaths as of July 30.
Two things need to be stated clearly at the outset. Africa CDC is proposing a trial, not deploying a vaccine. And Ervebo has never been shown to protect humans against Bundibugyo virus.
Why a Licensed Ebola Vaccine Does Not Cover This Outbreak
Ebola is not one virus. Ervebo is licensed for prevention of disease caused by Zaire ebolavirus, the species responsible for most previous outbreaks, and the vaccine works by presenting that species' surface glycoprotein to the immune system.
Bundibugyo is a different species, with a different glycoprotein. Antibodies raised against one do not necessarily neutralize the other, which is why licensure does not transfer. Bundibugyo was first identified in Uganda in 2007 and has historically carried case fatality rates in the range of 25 to 50 percent, lower than some other species but still severe.
WHO's expert groups reviewed this question earlier in the outbreak and concluded that Ervebo is not licensed for Bundibugyo virus disease and that evidence on cross-protection remains limited and inconclusive. Those advisers also recommended that all candidate products be used exclusively within clinical trials rather than deployed on the basis of assumption.
What Changed to Prompt the Proposal
The scientific case has strengthened over the past several weeks. A research letter published in the New England Journal of Medicine assessed cross-reactive Bundibugyo antibody responses in serum from people who had received licensed Ebola vaccines, adding to a body of work suggesting Ervebo may generate an immune response relevant to Bundibugyo. As STAT reported, that finding fueled calls to formally study the vaccine in the outbreak zone.
An immune response is not the same as protection. Antibody data are a plausibility signal that justifies a trial, not a substitute for one, and earlier work in primates is suggestive rather than conclusive.
Africa CDC is working with Médecins Sans Frontières on a two-dose design, in which a dose of Ervebo would be followed by a dose of an experimental vaccine developed against Sudan virus, a prime-boost approach that a primate study more than a decade ago suggested may broaden protection. IAVI, which is developing that Sudan candidate, has been in discussions about supplying doses.
Timing is the other driver, and it is the strongest practical argument for the proposal. Bundibugyo-specific vaccines are advancing but are not ready, and the outbreak is not waiting for them. The first vaccine designed specifically against Bundibugyo ebolavirus, developed by the Oxford Vaccine Group with the Serum Institute of India, entered phase 1 human trials in July, and CEPI is accelerating three candidates. A phase 1 study establishes safety and immune response in a small group, not effectiveness.
Who Would Be Enrolled First
If the proposal clears scientific and regulatory review, frontline health care workers are the population most likely to be enrolled first, and the reason is grim arithmetic.
Health workers in the DRC have been infected and killed in significant numbers during this outbreak. Responders have described shortages of protective equipment, diagnostics and hygiene supplies, and the outbreak is unfolding in eastern DRC where armed conflict has left health infrastructure thin and access unreliable.
Health workers are also an epidemiologically coherent trial population. They face known, repeated occupational exposure; they can be followed systematically, and protecting them preserves the response capacity the entire containment effort depends on. Enrolling them first is the design most likely to generate an answer quickly, because effectiveness signals emerge fastest in a group with high background exposure.
For U.S. households, the direct risk remains low. The CDC has confirmed no Bundibugyo cases diagnosed in the United States from this outbreak and continues to restrict entry for travelers recently in the DRC while routing permitted travelers from Uganda or South Sudan through designated airports for enhanced screening. The households with real exposure are a specific group: aid workers, missionaries, clinical volunteers, researchers and people with family in eastern DRC.
What Remains Unresolved
Several things are genuinely unknown, and they should not be papered over.
No trial has been approved. Whether Ervebo protects humans against Bundibugyo virus is unproven, and a trial could show no benefit. Reporting also differs on when advisers will formally take up the question, with Bloomberg describing a presentation in early August while WHO told STAT that its Strategic Advisory Group of Experts on Immunization would examine the idea at its next meeting in October. Supply is a further constraint, since Ervebo stockpiles are finite and are held against Zaire ebolavirus outbreaks elsewhere.
Watch for the outcome of the Africa CDC presentation, any WHO advisory group statement, and further WHO situation reports on case counts. MedicalDaily will report on whether a trial protocol is approved and when enrollment could begin.
Developing Story Timeline
July 31, 2026: Africa CDC's plan to present evidence to WHO vaccine advisers in support of an Ervebo trial against Bundibugyo virus is reported.
July 30, 2026: WHO reports 3,605 confirmed cases and 1,587 deaths in the DRC, making this the country's largest recorded Ebola outbreak.
July 22, 2026: A New England Journal of Medicine research letter reports cross-reactive Bundibugyo antibody responses after licensed Ebola vaccines.
May 28, 2026: WHO expert groups conclude that evidence on Ervebo cross-protection is limited and inconclusive and recommend that candidate products be used only within clinical trials.
May 15, 2026: DRC's Ministry of Health confirms an Ebola outbreak caused by Bundibugyo virus in Ituri Province.
Frequently Asked Questions
Is there a vaccine for the Ebola strain in this outbreak? No. There is no licensed vaccine for Bundibugyo ebolavirus.
What is Ervebo approved for? Prevention of Ebola disease caused by Zaire ebolavirus, a different species from the one driving this outbreak.
Does Ervebo protect against Bundibugyo virus? That is unknown. Some laboratory and animal data suggest a possible partial effect, but WHO has described the cross-protection evidence as limited and inconclusive, and no human effectiveness data exist.
Has a trial been approved? No. Africa CDC is presenting evidence in support of one. Any trial would require scientific and regulatory approval.
Who would participate first? Frontline health care workers are the likely initial population, given documented occupational exposure and infections among health workers in the DRC.
Is there a vaccine specific to Bundibugyo in development? Yes. The first Bundibugyo-specific candidate entered phase 1 human trials in July, and CEPI is accelerating three candidates. Phase 1 establishes safety, not effectiveness.
What is the risk to people in the United States? Low. No cases from this outbreak have been diagnosed in the United States, and entry restrictions and enhanced screening remain in place.
